Most patients start Viagra at 50 mg; 100 mg is the labelled increase

For most patients the recommended starting dose is 50 mg, used as needed about 1 hour before sexual activity. The dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. The start for most patients remains 50 mg. The maximum recommended dosing frequency is once per day. Sexual stimulation is required. Viagra is not indicated for women.

Results with all doses have been pooled, but scores showed greater improvement at the 50 and 100 mg doses than at 25 mg. Single oral doses of sildenafil up to 100 mg produced no clinically relevant changes in the ECGs of normal male volunteers. VIAGRA tablets contain sildenafil citrate equivalent to 25 mg, 50 mg, or 100 mg of sildenafil.

VIAGRA (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). VIAGRA (50 mg) did not potentiate the hypotensive effect of alcohol (0.5 g/kg) in healthy volunteers with mean maximum blood alcohol levels of 0.08%. In volunteers with mild and moderate renal impairment, the pharmacokinetics of a single oral dose of VIAGRA (50 mg) were not altered.

Do not combine with other PDE5 inhibitors. The maximum recommended dose of sildenafil is 100 mg. The maximum recommended dosing frequency is once per day. Sildenafil is contraindicated in patients using any form of organic nitrate, either regularly or intermittently.

Adults 65 years of age and older may use 25 mg as a single dose no more than once a day. For most patients the recommended starting dose is 50 mg, used as needed about 1 hour before sexual activity. The dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. VIAGRA tablets contain sildenafil citrate equivalent to 25 mg, 50 mg, or 100 mg of sildenafil. The maximum recommended dosing frequency is once per day. Sexual stimulation is required.

In fixed-dose studies, headache occurred in 16% at 25 mg, 21% at 50 mg, and 28% at 100 mg, versus 7% on placebo. Flushing occurred in 10% at 25 mg, 19% at 50 mg, and 18% at 100 mg, versus 2% on placebo. Dyspepsia occurred in 3% at 25 mg, 9% at 50 mg, and 17% at 100 mg, versus 2% on placebo. Abnormal vision occurred in 1% at 25 mg, 2% at 50 mg, and 11% at 100 mg, versus 1% on placebo. Nasal congestion occurred in 4% at 25 mg, 4% at 50 mg, and 9% at 100 mg, versus 2% on placebo. The most common adverse reactions reported in clinical trials (≥ 2%) are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. VIAGRA was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide.

VIAGRA is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients. VIAGRA is not indicated for use in females. There are no data with the use of VIAGRA in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Limited data indicate that sildenafil and its active metabolite are present in human milk. Viagra is indicated for erectile dysfunction. Sexual stimulation is required. Store at 25 C (77 F); excursions permitted to 15 to 30 C (59 to 86 F).

VIAGRA (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). VIAGRA (50 mg) did not potentiate the hypotensive effect of alcohol (0.5 g/kg) in healthy volunteers with mean maximum blood alcohol levels of 0.08%. Single oral doses of sildenafil up to 100 mg produced no clinically relevant changes in the ECGs of normal male volunteers. In volunteers with mild and moderate renal impairment, the pharmacokinetics of a single oral dose of VIAGRA (50 mg) were not altered. For most patients the recommended starting dose is 50 mg. The dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg.